ClinicalTrials.gg
CompletedNCT01045902Updated Jan 11, 2010

BAY12-8039, iv/Oral Pulmonary Abscess/Aspiration Pneumonia

A Phase 3 interventional study of Avelox (Moxifloxacin, BAY12-8039) and Sulbactam/Ampicillin in Pneumonia, Aspiration and Lung Abscess, sponsored by Bayer. Completed at 15 sites in Germany. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2010-01-11.

Sponsored by Bayer · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
139
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Study summary

The purpose of this trial is to determine the efficacy and safety of Moxifloxacin in comparison to Sulbactam/Ampicillin in the treatment of pulmonary abscesses and aspiration pneumonia.

02

Conditions studied

  • Pneumonia, Aspiration
  • Lung Abscess

Browse trials for

Keywords

  • Pulmonary Abscess
  • Aspiration Pneumonia
03

In context

Pneumonia, Aspiration

73 studies on the registry are indexed under Pneumonia, Aspiration; 12 are open to participants now.

This study's enrollment of 139 is above the median of 113 across 38 interventional studies indexed under Pneumonia, Aspiration.

Browse Pneumonia, Aspiration studies →

Lead sponsor

Bayer is the lead sponsor of 1,674 studies on the registry; 51 are open to participants now.

Of its 214 completed or terminated interventional studies of FDA-regulated products, 132 (62%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Male or female patients aged 18 years or above
  • The primary diagnosis is community or hospital acquired primary pulmonary abscess or aspiration pneumonia, requiring initial parenteral treatment

Exclusion criteria

Exclusion Criteria:

  • Known to fluoroquinolones and/or ß-lactams
  • Patients with mechanical ventilation lasting more than 48 hours prior to enrollment, with poststenotic pneumonia, infarction pneumonia, pulmonary tuberculosis, lung abscess/pneumonia with concomitant endocarditis
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
139 participants (actual)

Study arms

  • Experimental
    Arm 1

    Drug: Avelox (Moxifloxacin, BAY12-8039)

  • Active comparator
    Arm 2

    Drug: Sulbactam/Ampicillin

Interventions

  • Moxifloxacin, 400 mg iv, od, switch after 6 doses (6 days) to 400 mg Moxifloxacin oral, od

  • DrugSulbactam/Ampicillin

    Drug pages: Sulbactam · Ampicillin

    Sulbactam/Ampicillin, 3 g iv, tid, switch after 18 doses (6 days) to 750 mg Sulbactam/Ampicillin oral, bid

06

What researchers measure

Primary outcomes

  1. Adverse events occuring after first application of study medication up to the test of cure visit for non-serious adverse events

    Time frame: Up to 30 days after end of treatment with study medication for serious adverse events

Secondary outcomes

  1. Clinical Response

    Time frame: Regulary doing i.v. treatment

07

Study locations

15 sites
  • Mannheim, Baden-Württemberg 68167, Germany
  • Nürnberg, Bayern 90419, Germany
  • Regensburg, Bayern 93053, Germany
  • Treuenbrietzen, Brandenburg 14929, Germany
  • Frankfurt, Hessen 60596, Germany
  • Hildesheim, Niedersachsen 31134, Germany
  • Rotenburg, Niedersachsen 27356, Germany
  • Lüdenscheid, Nordrhein-Westfalen 58515, Germany
  • Oberhausen, Nordrhein-Westfalen 46045, Germany
  • Paderborn, Nordrhein-Westfalen 33098, Germany
  • Magdeburg, Sachsen-Anhalt 39112, Germany
  • Leipzig, Sachsen 04129, Germany
  • Lübeck, Schleswig-Holstein 23538, Germany
  • Berlin, 13353, Germany
  • Berlin, 14165, Germany
08

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Feb 2001 and a completion of Jan 2005. It does not say whether these dates are actual or estimated.

How these figures are worked out, and which studies are left out of them.

Registered
Jan 8, 2010
First posted
Jan 11, 2010
Start
Feb 2001
CompletionActual
Jan 2005
Last update
Jan 11, 2010
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jan 11, 2010, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT01045902
Lead sponsor
Bayer
First posted
Jan 11, 2010
Start date
Feb 2001
Completion
Jan 2005
Last update
Jan 11, 2010

Study contacts

Bayer Study Director
study director · Bayer
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jan 2010. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Moxifloxacin

Start the discussion